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Abstract: Active immunisation against gonadotropin releasing hormone (GnRH) is a 
potential alternative to surgical castration. This study focused on the development of a GnRH 
subunit lipopeptide vaccine. A library of vaccine candidates that contained one or more (up to 
eight) copies of monomeric or dimeric GnRH peptide antigen, an adjuvanting lipidic moiety 
based on lipoamino acids, and an additional T helper epitope, was synthesised by solid phase 
peptide synthesis. The candidates were evaluated in vivo in order to determine the minimal 
components of this vaccine necessary to induce a systemic immune response. BALB/c mice 
were immunised with GnRH lipopeptide conjugates, co-administered with or without 
Complete Freund’s Adjuvant, followed by two additional immunisations. Significant GnRH-
specific IgG titres were detected in sera obtained from mice immunised with four of the 
seven lipopeptides tested, with an increase in titres observed after successive immunisations. 
This study highlights the importance of for epitope optimisation and delivery system design 
when producing anti-hapten antibodies in vivo. The results of this study also contribute to the 
development of future clinical and veterinary immunocontraceptives.  
 
Keywords: gonadotropin releasing hormone; lipopeptide; vaccine; T helper; murine 
immunogenicity 
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1. Introduction 
Our understanding and approaches to block or limit the release of reproductive hormones in 
an attempt to limit their influence on cancers has progressed to the development of 
immunotherapies. In spite of low immunogenicity, active immunisation against gonadotropin 
releasing hormone (GnRH) has received considerable attention because of potential 
applications in immunocontraception. An active area of research is the development of 
synthetic GnRH-based vaccines against reproductive hormone-dependent male and female 
cancers.1 Studies have shown that immunisation against GnRH can reduce prostate levels of 
testosterone similar to surgical castration in numerous mammalian models, including mice 
and humans.2, 3 Immunisation of both males and females against GnRH can have a profound 
effect on fertility through the reduction in sex steroids and cessation of gametogenesis. 
Hence, there is a potential for GnRH therapeutics to be used either as a semi-permanent 
contraceptive or to extend the postnatal anovulatory period.4, 5  
In the 1970s a number of groups attempted to produce antibodies against GnRH by co-
administration with Complete Freund’s Adjuvant (CFA). However, these attempts were 
unsuccessful in producing high anti-GnRH antibody titers.6 Many small molecules like 
peptides (haptens) are successful immunogens only if they are attached to macromolecules 
(carriers). It is often necessary to modify these haptens for coupling with carriers to make a 
stable carrier–hapten complex.7 Selection of a suitable carrier system, hapten density 
(hapten:carrier molar ratio), and conjugation methods are critical for developing an optimal 
vaccine against haptens.8, 9 The first alum-adjuvanted vaccine which was successful in 
producing antibodies against GnRH was conjugated to a tetanus toxoid carrier.10 A number of 
other fusion proteins have been prepared for the production of anti-GnRH antibodies that 
employ conjugation to diphtheria toxoid (e.g. Improvac®), keyhole limpet hemocyanin (e.g. 
GonaCon™) or ovalbumin, with many of them available commercially for veterinary use.11-15 
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Another recombinant fusion protein consisting of GnRH and diphtheria toxoid was successful 
in phase I/II clinical trials.16 
Synthetic subunit vaccine systems eliminate the need for large carrier proteins, which are 
often associated with adverse effects in the host.17 Since subunit vaccines are composed of 
different individual components (i.e. epitopes, carriers, adjuvants), they are highly 
customisable. This makes them valuable tools for developing vaccines against weak 
immunogens, such as GnRH.18 Lipopeptides can form a synthetic subunit vaccine as one 
entity that includes all components (adjuvant, carrier and antigen) required by a successful 
vaccine, eliminating the need for co-administration with an adjuvant.19, 20 
High antibody titers were generated when multiple copies of a peptide were incorporated into 
a multiple antigenic peptide system with a branched polylysine core.20 Immunogenicity was 
further enhanced by the incorporation of lipoamino acid (LAA) residues with this polylysine 
system, which led to the development of novel candidates for vaccines against a variety of 
disease states, including cancer. The lipid moieties in the lipopeptide system serve to mimic 
the action of bacterial adjuvants such as Pam3Cys and Pam2Cys.21 Lipopeptide constructs 
have been found to mediate significant immunogenic effects without additional adjuvants.22, 
23
 
The development of a GnRH-based subunit lipopeptide vaccine for use as an 
immunocontraceptive therapy has previously received attention.24 In this study, we aimed to 
define the minimal components necessary for the induction of a systemic immune response 
against GnRH. The immunogenicity of the GnRH decapeptide (EHWSYGLRPG) was 
enhanced by incorporating it into the lipopeptide systems.  
 
2. Results and Discussion 
2.1. Peptide synthesis 
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Lipopeptides 1-5 (Figure 1) were synthesised by manual and microwave-assisted solid-phase 
protocols with Boc chemistry.25 Lipidic moieties were prepared from their 1-bromoalkanes 
using the method of Gibbons et al. and were used as a mixture of enantiomers in subsequent 
synthesis.26 Amino acid couplings involved an activation of residues with DIPEA in DMF, 
followed by in situ neutralization in the presence of HATU or HBTU. The carbohydrate core 
for vaccine construct 2 was synthesised from a D-glucose derivative that bore an adipate 
linker and four tert-butoxycarbonyl protected aminopropyl groups as attachment points for 
GnRH peptide epitopes.27, 28 
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Figure 1. Structure of GnRH lipopeptide subunit vaccines (1-6).  
 
The first series of compounds (1-3, Figure 1) contained four copies of the GnRH peptide 
epitope with three copies of 12-carbon LAAs (C12) separated by glycine spacers (1 and 2) or 
16-carbon LAAs (C16) (3) attached to either a poly-lysine (1 and 3) or onto a glucose core 
(2). GnRH-based vaccine candidates bearing Pam2Cys adjuvanting lipid moiety and T helper 
epitope derived from the L chain of influenza virus hemagglutinin 
(GALNNRFQIKGVELKS) was effective in a female mouse model.29 A similar construct (4) 
consisting of two C16 lipid moieties was therefore used in this study. To investigate the 
immunogenic potential of the GnRH epitope, four copies of a tandem GnRH dimer were 
synthesised on a poly-lysine lipopeptide to yield 8 copies of the epitope in total (5). The 
presentation of GnRH was enhanced by replacing the Gly residue at position 6 in the parent 
peptide sequence with a D-Cys (pEHWSYcLRPG30 and conjugated to a linear T helper 
lipopeptide (6’) using Michael addition (Figure 2).31 The site-specific conjugation allowed 
for both terminal regions of GnRH to display the free amino groups important for immune 
system recognition (6). The lipopeptide was designed to have only two 16-carbon LAAs at 
the N-terminus, with an additional Ser spacer for improved solubility. These modifications 
led to improved yields (70%) compared to the original design that incorporated a lipidic tail 
similar to 3 (4%). In compounds 4 - 6, serine residues were used as spacers between the lipid 
moiety and epitopes, a modification that was previously reported to enhance the immune 
response of lipopeptides.32 
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Figure 2. Conjugation of [D-Cys6]GnRH* to maleimide conjugated adjuvant (6’), to form 6. 
 
2.2. In vitro peripheral blood mononuclear cell (PBMC) toxicity assay 
Numerous methods exist to evaluate cellular toxicity; most of them use cell cultures to screen 
for toxicity by either observing changes in normal cell function or detecting dead cells with 
stain-based assays. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) bromide 
assay has been widely used for determining the cytotoxicity of compounds.33 We adopted this 
method with the peripheral blood mononuclear cells (PBMCs) as a model to evaluate the 
cytotoxicity of the library of lipopeptide vaccine candidates.  This model is particularly 
relevant for testing of drug candidates, and for the assessment of potential toxic risks 
associated with clinical trials. 
In this assay, vaccine candidates 1-6 were tested at four rising concentrations (10, 50, 100 
and 200 µM). A slight decrease in cell viability was observed by the highest concentration of 
the vaccine constructs after 48 h; however, it was not statistically significant compared to the 
negative control (Figure 3, p>0.05).  
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Figure 3. Percentage of PBMC viability compared to phosphate-buffered saline (PBS) after 
48 h incubation with the lipopeptide vaccine candidates 1-6 at four concentrations. Data 
represented as mean ± SEM. Statistical analysis was performed using one-way ANOVA 
followed by the Dunnett’s post hoc test and compared to the PBS group. 
 
2.3. Murine immunogenicity of synthetic GnRH vaccine candidates 
The first study was performed to determine the ability of the GnRH lipopeptides to induce an 
immune response when four copies of GnRH were incorporated into polylysine or 
carbohydrate scaffolds (1-3). Compounds 1-3 without T helper epitope were compared to 
compound 4, which consisted of one copy of GnRH along with a T helper epitope. All 
lipopeptide vaccine candidates were dissolved in PBS at a concentration of 1 µg.µL-1 and 
administered with CFA to adjuvant a significant response to each construct. It was proposed 
that the immunogenicity of the GnRH hapten would benefit from increased molecular weight, 
increased copy number (possible B-cell receptor clustering), and the incorporation of a lipid 
adjuvant. It was anticipated that GnRH linked by the lysine residues of the polylysine core (1 
and 3) would produce a structure that was large enough to be recognised and processed by 
the immune system. Since the spatial arrangement may play a part in the immunogenicity of 
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synthetic subunit vaccines, a carbohydrate scaffold was used as a peptide antigen carrier to 
assemble 2. However, the first study using compounds 1-4 showed that compound 4 
administered with CFA was the only compound to produce significant GnRH-specific IgG 
antibody titers (Figure 4). This demonstrated that the lipopeptide system alone was 
insufficient to adjuvant GnRH and required the incorporation of the T helper epitope or 
another strategy to stimulate a significant immune response in this model. To this end we 
designed two additional compounds to improve the immunogenicity of the anti-GnRH 
vaccine construct.  
 
 
Figure 4. GnRH-specific serum IgG titers (log10) at day 64 after primary immunisation in 
response to intramuscular immunisation of BALB/c mice as determined by ELISA of 
individual sera from the first study (1-4). Mean IgG titers are represented by a bar. Primary 
immunisation on day 0 was followed by boosts on days 28 and 56. Statistical analysis was 
performed using a one-way ANOVA followed by the Tukey post hoc test and compared to 
the PBS group (***, p < 0.001). 
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Lipidated GnRH dimers have previously been shown to elicit an antibody response in murine 
models when administered with CFA.31 Therefore, in order to increase the possibility of 
inducing an immune response to GnRH, the peptide was dimerised in tandem and attached to 
the lipopeptide system in four copies (8 GnRH epitopes in total; 5). The vaccine 5 co-
administered with CFA produced IgG titers comparable to the positive control 4 over the 
course of the study. Notably, when mice were administered with 5 alone (no CFA), 
comparable antibody titres (p > 0.05) to 5 with CFA were achieved at day 63, (Figure 5). 
This demonstrated the adjuvanting activity of the lipopeptide in the construct. It is plausible 
that dimerization of the GnRH epitope in the construct induced an immune response either 
due to the formation of small receptor clusters co-localised by binding of polyvalent antigens 
or by the creation of epitopes in the junction of the dimer.34 In a previous study multiple 
copies of GnRH was added to a fragment of human IgG and T helper epitope derived from 
measles virus. It was shown that a significantly greater antibody response was elicited 
compared to that with same sequence but only a single copy of GnRH epitope.35  
Interestingly, the vaccine candidate 6 in PBS induced slightly higher GnRH-specific IgG 
titers in mice than 4 with CFA (Figure 5). Both constructs consisted of identical principal 
components (GnRH, T helper epitope and lipid adjuvant), yet arranged in different 
configurations and conjugated through alternate bonds and positions. Our findings are 
consistent with a previous study where thioester linkages elicited higher antibody titers when 
compared to a library of alternative bonds.36 It was suggested that different spatial 
arrangements of antigen, carrier, and adjuvant, and the presence of different bonds were 
responsible for variation in antibody titers. 
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Figure 5. GnRH-specific serum IgG titers (log10) at day 63 after primary immunisation in 
response to intramuscular immunisation of BALB/c mice as determined by ELISA for 
individual sera from the second study (4-6). Mean IgG titers are presented as a bar. Primary 
immunisation on day 0 was followed by boosts on days 28 and 56. Statistical analysis was 
performed using a one-way ANOVA followed by the Tukey post hoc test, when each 
compound was compared to the PBS group (**, p < 0.01; ***, p < 0.001) or when 5 with 
CFA (5 + CFA) was compared to 5 alone (ns, p>0.05). 
 
3. Conclusion 
This study outlines the synthesis, cytotoxicity and immunogenicity of a library of novel 
lipopeptide subunit vaccines for GnRH. Self-adjuvanting lipopeptide GnRH vaccine 
candidates that contained multiple GnRH monomer/dimer epitopes or a thioester-linked 
GnRH helper epitope system were identified and developed. The investigation of the 
structure-activity relationship and optimal epitope configuration reinforced that the inclusion 
of both B and T helper epitopes has a significant effect on systemic anti-GnRH IgG titers. It 
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was also demonstrated that alternative strategies, such as using multiple copies of a peptide 
dimer, were successful without the need for additional helper epitopes, which can be useful 
because helper epitope selection can be challenging, particularly when developing a vaccine 
to be tested on cross-species platforms.39, 40  
This study confirmed the self-adjuvanting activity of the LAA moieties by eliciting 
comparable anti-GnRH IgG titers to the titers obtained from the constructs co-administered 
with CFA. Further analysis is necessary to optimise and understand the mechanisms 
responsible for the immunogenicity of these lipopeptide vaccine candidates and their 
epitopes. These findings significantly advance out understanding of anti-hapten subunit 
vaccine design and could contribute to the future development of a commercially viable 
subunit-based GnRH vaccine. 
 
4. Experimental Section 
4.1. Materials and methods 
Unless otherwise stated, all chemicals were of analytical grade or equivalent. Acetic 
anhydride (Ac2O) was supplied by Univar (Ingleburn, NSW, Australia). N,N-
Dimethylformamide (DMF) was obtained from EMD (Darmstadt, Germany). HATU, HBTU, 
Boc- and Fmoc-L-amino acids, and resins were obtained from Mimotopes (Clayton, VIC, 
Australia), Novabiochem (Läufelfingen, Switzerland) and Peptides International (Louisville, 
Kentucky). Di-tert-butyldicarbonate was purchased from Auspep (Melbourne, VIC, 
Australia). Acetic acid (AcOH), N,N- dichloromethane (DCM), diethyl ether, 
diisopropylethylamine (DIPEA), HCl, hydrogen bromide in AcOH, ninhydrin, triethylamine 
(TEA) and trifluoroacetic acid (TFA) were supplied by Merck (Kilsyth, VIC, Australia). 
HPLC and MS grade acetonitrile (MeCN) and methanol (MeOH) were supplied by Scharlau 
(Port Adelaide, SA, Australia). Anhydrous hydrofluoric acid (HF) was supplied by BOC 
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gases (Sydney, NSW, Australia). For in vivo experiments, Dulbecco’s modified Eagle’s 
medium (DMEM), Hank’s balanced salt solution (HBSS), 2-[4-(2-hydroxyethyl)piperazin-1-
yl]ethanesulfonic acid (HEPES) and PBS were obtained from GIBCO (Mulgrave, VIC, 
Australia). Isopropanol was sourced from Lab-Scan Pty Ltd (Dublin, Ireland). All other 
reagents were purchased from Sigma-Aldrich (Castle Hill, NSW, Australia).  
A Kel-F HF apparatus (Peptide Institute, Osaka, Japan) was used for HF cleavage. Thin layer 
chromatography (TLC) was carried out on Kieselgel 60 F254 silica gel coated aluminum 
plates (Merck, Darmstadt, Germany). All TLCs were visualised by 20% H2SO4 or p-
anisaldehyde followed by heating. Tetrahydrofuran (THF), DCM and CHCl3 were dried by 
distillation with sodium/benzophenone, calcium hydride and calcium chloride, respectively, 
then used immediately or stored with 4Å molecular sieves. 
1H-NMR spectra were recorded on a BRUKER Avance spectrometer at 300MHz or 500MHz 
in CDCl3. ESI-MS was performed on a triple quadrupole Perkin-Elmer-Sciex API3000 mass 
spectrometer using a solvent mixture of A [H2O + 0.1% AcOH] and B [MeCN/H2O + 0.1% 
AcOH]. Data were acquired and analysed using Analyst 1.4 (Applied Biosystems/MDS 
Sciex, Toronto, Canada) software.  
Reverse-phase-high performance liquid chromatography (RP-HPLC) analysis was carried out 
using a Shimadzu instrument (Kyoto, Japan), with a Grace Vydac (Columbia, MD, USA) 
Protein/Peptide column. Analysis was achieved using a gradient of solvent A 
(99.9%H2O/0.1%TFA) and solvent B (90%MeCN/H2O/0.1%TFA). A gradient of 0-100% 
solvent B (C4), 40-70% solvent B (C4’), or 40-80% solvent B (C4”) over 30 min was 
employed and absorbance detected at 214 nm. Crude peptides were then purified using a 
Waters Delta Prep 600 (Milford, MA, USA) or Shimadzu (LC-20AT, SIL-10A, CBM-20A, 
SPD-20AV, FRC-10A; 20 mL.min-1) preparative RP-HPLC with a Grace Vydac C4/C18 
column. Separation was achieved using a gradient of solvent A and solvent B at a flow rate of 
  
 
14
10 mL.min-1 detected at 230 nm. All peptides were characterised using ESI-qQTOF on an 
Applied Biosystems QSTAR Pulsar mass spectrometer (Foster City, CA, USA) or ESI-MS 
on a triple quadrupole API 3000 (Sciex/Applied Biosystems). 
 
4.2. Chemistry 
4.2.1. 6-Maleimidocaproic acid41 
Maleic anhydride (2.94 g, 30 mmol) and 6-aminocaproic acid (3.94 g, 30 mmol) were 
refluxed in AcOH (70 mL) overnight. Ac2O (2.83 mL, 30 mmol) was added dropwise and 
reflux continued for a further 1 h. The acetic acid was co-evaporated with toluene in vacuo to 
yield yellow syrup. The material was purified over SiO2 (DCM:MeOH, 10:0.7) affording a 
cream crystalline solid in 57% yield (3.58 g): Rf (DCM:MeOH, 10:0.7) = 0.50; ESI-MS 
(C10H13NO4, 211.1): m/z = 212.0 [M+H+] (calcd. 212.1), 423.1 [M+2H+] (calcd. 423.2); 1H 
NMR: δ = 6.95 (2H, s, CH=CH), 3.35 (2H, t, J 7.4 Hz, NCH2), 2.15  (2H, t, J 7.2 Hz, 
CH2COO-), 1.45 (4H, m, 2CH2), 1.18 (2H, m, CH2). 
 
4.2.2. 2-tert-Butoxycarbonylaminododecanoic acid lipoamino acid (Boc-C12-OH)42 
2-Aminododecanoic acid was synthesised as described in the literature with 1-bromodecane 
and diethyl acetoamidomalonate.26 The free amine of 2-aminohexadecanoic acid was then 
Boc-protected by reaction with di-tert-butyl dicarbonate in a basic environment as previously 
reported.26, 43 C12 was prepared to afford the pure product in 54.0% yield (1.31 g): Rf = 0.65 
(DCM/MeCN/AcOH); ESI-MS (C17H33NO4, 315.2): m/z = 316.4 [M+H]+ (calcd. 316.2), 
338.2 [M+Na]+ (calcd. 338.2); 1H NMR: δ = 4.94-4.92 (1H, d, J 7.1 Hz, OCONH), 4.26 (1H, 
m, α-CH), 1.82-1.67 (2H, m, β-CH), 1.42 (9H, s, C(CH3)3), 1.23 (16H, bs, 8CH2), 0.86 (3H, 
t, J 7.0 Hz, CH3). 
 
  
 
15
4.2.3. 2-tert-Butoxycarbonylaminohexadecanoic acid lipoamino acid (Boc-C16-OH)44 
2-Aminohexadecanoic acid was synthesised as described in the literature with 1-
bromotetradecane and diethyl acetoamidomalonate. The free amine of 2-aminohexadecanoic 
acid was then Boc-protected by reaction with di-tert-butyl dicarbonate in a basic environment 
as previously reported.26 The C16 product was prepared to yield (78%) the pure product (1.89 
g): Rf = 0.68 (DCM/MeCN/AcOH); ESI-MS (C21H41NO4, 371.6): m/z = 394.3 [M+Na]+ 
(calcd. 374.6); NMR: δ = 4.92 (1H, m, OCONH), 4.26 (1H, m, α-CH), 1.93-1.58 (2H, m, J 
7.5 Hz, β-CH), 1.45 (9H, s, C(CH3)3), 1.25 (24H, bs, 12CH2), 0.86 (3H, t, J 6.9 Hz, CH3). 
 
4.2.4. 2-((1-(4,4-Dimethyl-2,6-dioxocyclohexylidene)ethyl)amino)hexadecanoic acid 
(Dde-C16-OH)45 
5,5-Dimethyl-1,3-cyclohexanedione (2.5 g, 17.8 mmol) was dissolved in DCM (15 mL). 4-
Dimethylaminopyridine (435 mg) and TEA (5 mL) were then added and the mixture was 
stirred for 10min. Ac2O (2.2 mL) was added and the mixture was stirred under Ar for 2 days. 
The solvent was removed in vacuo by co-evaporation of the crude product in ethyl acetate 
(EtOAc) (50 mL) with toluene and then washed with 5% HCl (3 x 50 mL) and dried with 
MgSO4. The solvent was evaporated to produce an oil which was filtered through a column 
of silica (Hex:EtOAc, 3:2). The EtOAc from the mixture obtained was evaporated in vacuo to 
afford an orange oil, which was then cooled to yield pale yellow crystals (2-acetyldimedone, 
Dde-OH) in 72% yield (2.35 g): Rf (Hex:EtOAc, 3:2) = 0.76; ESI-MS (C10H15NO2, 181.1): 
m/z =  182.2 [M+H]+ (calcd. 182.1); 1H NMR: δ = 2.59 (s, 3H, C=C(CH3)2) ; 2.52, 2.35 (2s, 
4H, 2CH2) ; 1.06 (s, 6H, 2CH3). 
2-Amino-D,L-hexadecanoic acid hydrochloride (2 g, 7.48 mmol) and Dde-OH (1.5 g, 8.23 
mmol) were suspended in ethanol (30 mL). TEA (2.6 mL) was added and the mixture 
refluxed under an inert atmosphere for 2 days. The solvent was evaporated and the crude 
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product taken up in EtOAc (50 mL) and washed with 5% HCl (3 x 30 mL) then dried over 
MgSO4. The solvent was evaporated to afford a solid which was triturated with diethyl ether 
to afford the pure product as a white solid in 55% yield (1.78 g): Rf (CHCl3:MeOH, 10:0.7) = 
0.58; ESI-MS (C26H45NO4, 435.3): m/z = 436.4 [M+H]+ (calcd. 436.3); 1H NMR: δ = 4.38 
(1H, dd, J 6.3, 6.6 Hz, α-CH), 2.52 (3H, s, C(NH)CH3), 2.40 (4H, s, 2CH2CO), 2.04-1.90 
(2H, m, β-CH2), 1.46-1.23 (24H, m, 12CH2), 1.02 (6H, s, C(CH3)2), 0.86 (3H, t, J 6.9 Hz, 
CH3). 
 
4.2.5. Synthesis of lipopeptides 
All peptides were synthesised using standard manual solid phase peptide synthetic protocols 
and then purified by RP-HPLC. Lipopeptides 1-5 were synthesised using p-4-methyl 
benzhydryl amine (p-MBHA; substitution 0.45 mmol.g-1) resin (Peptides International, 
USA), which was swollen in DMF/DIPEA for approximately 1 h. Synthesis was carried out 
using 4 equiv. Boc-L-amino acids. Lipopeptides were synthesised using 8 equiv. of activated 
amino acids after the addition of the second Lys residue. The peptides were then coupled 
using amino acids preactivated with an equimolar amount of 0.5 M HBTU or HATU in DMF 
and 6 equiv. DIPEA, then mixed with the resin for 30-45 min at r.t. or for 5-10 min at 70 °C, 
20 W. For Boc chemistry synthesis, Boc protecting groups were used for the α-amino-
termini; Tos for Arg; DNP and Bom for His; Bzl for Ser; For for Trp; 2-Br-Z for Tyr; 2Cl-Z 
for Lys; Xan for Asn and Gln; and OcHx for Glu. Boc-C12-OH and Boc-C16-OH were used 
to assemble the N-terminal lipid adjuvant. Boc-Lys(Boc)-OH·DCHA salt was neutralised 
using 0.5 M NaHSO4/EtOAc, dried in vacuo and utilised for the synthesis of the polylysine 
carrier. The Boc protecting groups were removed from the amino acids using neat TFA. Prior 
to final Boc deprotection, the formyl/Fmoc and DNP protecting groups were removed with 
20% piperidine in DMF and 20% 2-mercaptoethanol/10% DIPEA in DMF, respectively. The 
  
 
17
resin was washed with DMF after each manipulation. After the last coupling, all terminal Boc 
and Fmoc groups were removed. The resin was then washed consecutively with DMF, DCM 
and MeOH and left to dry in vacuo overnight. The peptides were cleaved from the resin using 
the high HF method at a concentration of 10 mL.g-1 of resin and 5% p-cresol at -5-0 ˚C for 1-
2 h. Following this, the peptide was precipitated in diethyl ether, washed through a 
polyethylene frit, then dissolved in 1:1 MeCN:H2O and lyophilised.  
Synthetic adjuvants for conjugation to [D-Cys6]GnRH were assembled using microwave-
assisted Fmoc solid phase peptide synthetic protocols. The peptides were synthesised on Rink 
Amide MBHA LL (100-200 mesh, 0.34 mmol.g-1) resin (Peptides International, USA), which 
was swelled in DMF/DIPEA for approximately 15 min. Peptides were then coupled using 
amino acids that had been activated for 1 min with an equimolar amount of 0.5 M HATU in 
DMF and 5 equiv. DIPEA, then mixed with the resin for 10 min at 70 °C, 20 W. The 
coupling efficiencies were monitored using the ninhydrin test calculated by reading the 
absorbance at 570 nm. If the coupling efficiency was below 99.6%, the coupling was 
repeated until the required efficiency was achieved. For Fmoc chemistry synthesis, Fmoc 
protecting groups were used for the α-amino-termini; Pbf for Arg; Trt for Asn, Cys, His, and 
Gln; tBu for Ser; Boc for Trp and Lys; and OtBu for Glu. Dde-C16-OH was used to assemble 
the N-terminal lipid adjuvant. The Fmoc protecting groups were removed from the amino 
acids using 20% piperidine/DMF. Dde groups were removed using 2% hydrazine hydrate in 
DMF. After each manipulation the resin was washed with DMF. After the last coupling, the 
resin was washed consecutively with DMF, DCM and MeOH then left to dry in vacuo 
overnight. The peptides were cleaved from the resin using 95% TFA/2.5% H2O/2.5% TIPS 
(10-25 mL.g-1) for 2 h at r.t. Following this, the slurry was dried, precipitated in diethyl ether, 
then dissolved in 1:1 MeCN:H2O and lyophilised.  
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Compound
 
1; purified yield: 5.0 mg, 23.3%; HPLC: tR (C4) = 20.60 min; ESI-MS 
(C278H402N76O60, 5768.6): m/z = 825.4 [M+7H]+ (calcd. 825.1), 962.7 [M+6H]+ (calcd. 
962.4), 1154.8 [M+5H]+ (calcd. 1154.7), 1444.0 [M+4H]+ (calcd. 1443.2), 1923.8 [M+3H]+ 
(calcd. 1923.9). 
Compound
 
2; purified yield: 5.8 mg, 26%; HPLC: tR (C4) = 20.63 and 21.47 min; ESI-MS 
(C284H413N75O64, 5901.8): m/z = 846.4 [M + 7H]7+ (calcd. 844.1), 984.5 [M + 6H]6+ (calcd. 
984.5), 1181.4 [M + 5H]5+ (calcd. 1181.2).  
Compound
 
3; purified yield: 5.0 mg, 25%; HPLC: tR (C4) = 21.27 min; tR (C4’) = 20.10 min; 
ESI-MS (C290H426N76O60, 5936.3): m/z = 849.4 [M+7H]7+ (calcd. 849.0), 990.5 [M+6H]6+ 
(calcd. 990.5), 1188.9 [M+5H]5+ (calcd. 1188.3), 1485.1 [M+4H]4+ (calcd. 1485.1). 
Compound
 
4; purified yield: 2.0 mg, 56%; HPLC: tR (C4) = 32.34 min; ESI-MS 
(C179H291N47O44, 3805.51): m/z = 636.4 [M+6H]6+ (calcd. 635.2), 763.1 [M+5H]5+ (calcd. 
762.1), 953.2 [M+4H]4+ (calcd. 952.3), 1270.9 [M+3H]3+(calcd. 1269.5), 1905.8 [M+2H]2+ 
(calcd. 1903.7). 
Compound
 
5; purified yield: 8.0 mg, 8%; HPLC: tR (C4) = 22.00, 22.37 min; tR (C4’) = 
20.90, 22.40 min; ESI-MS (C496H695N139O117, 10475.3): m/z = 953.7 [M+11H]11+ (calcd. 
953.3), 1049.1 [M+10H]10+ (calcd. 1048.5), 1165.2 [M+9H]9+ (calcd. 1164.9), 1311.1 
[M+8H]8+ (calcd. 1310.4), 1498.2 [M+7H]7+ (calcd. 1497.5), 1747.7 [M+6H]6+ (calcd. 
1746.9).  
 
4.2.6. Thioester conjugation of [D-Cys6]GnRH to maleimide adjuvant (6)  
The maleimide-T helper peptide adjuvant system, 6’ (2.0 mg), was dissolved in DMF (2 mL). 
Reduced (by 10 equiv. tris(2-carboxyethyl)phosphine, then purified) [D-Cys6]GnRH (2.0 mg) 
in PBS (18 mL) was then added, the reaction degassed, and left to stir at r.t. under N2 for 5 h. 
The product (6) was then purified using RP-HPLC and characterised with ESI-MS. 
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Compound 6’; purified yield: 88 mg, 95%; HPLC: tR (C4) = 24.20 min; ESI-MS 
(C123H211N29O29, 2559.6): m/z = 1281.0 [M+2H]2+ (calcd. 1281.3), 854.3 [M+3H]3+ (calcd. 
854.9). 
Compound 6; purified yield = 2.1 mg, 70%; HPLC: tR (C4) = 22.32 min; tR (C4”) = 15.60, 
15.93 min; ESI-MS (C179H288N46O42S, 3788.2): m/z = 758.6 [M+5H]5+ (calcd. 758.6), 947.9 
[M+4H]4+ (calcd. 948.1), 1264.0 [M+3H]3+ (calcd. 1263.7), 1895.4 [M+2H]2+ (calcd. 
1895.1). 
 
4.3. PBMC isolation and In vitro cell toxicity assay 
Assay was undertaken with the approval from the University of Queensland Ethics 
Committee (Ethics Approval Number: 2009000661). Blood samples (4 mL) were taken from 
a healthy adult consented volunteer and PBMCs were isolated by Ficoll gradient after 
centrifugation at 400 g for 30 min. The buffy coat layer including mononuclear cells was 
removed and washed three times with RPMI 1640 (4 mL). After the last washing step, cells 
were resuspended in 10% FBS:RPMI and seeded at 1x106 cells/mL in a 96-well flat bottom 
plates (TPP), activated by adding 10 µg.mL-1 of phytohemagglutinin and incubated at 37 °C 
in a 5% CO2 atmosphere. After 1 h incubation compounds were added at 10 µL/well in at 10, 
50, 100 and 200 µM. MTT (10 µL, 10 mg/mL) (Sigma-Aldrich) was added to each well and 
incubated for 4 h. 100 µL of acidified isopropanol (0.1 N HCl) was added to dissolve the 
formazan crystals and left to incubate at 37 °C for 30 min. A Molecular Devices SpectraMax 
250 microplate reader (Sunnyvale, CA, USA) was used to measure the absorbance of each 
well at 570 nm, with background subtracted at 690 nm. The percentage of viable cells for 
each compound was calculated by comparing absorbance with PBS positive control. SDS 
was used as a negative control. 
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4.4. Immunisation protocol 
All protocols were approved by The University of Queensland Animal Ethics Committee 
(AEC#SCMB/005/11/ARC) and carried out according to their guidelines. Female BALB/c 
mice were used for immunisation. Mice (n = 6-8/group) received a primary intramuscular 
(i.m.) dose of 50 µg of immunogen in a total volume of 50 µL of PBS. Two boosts (same as 
the primary dose) were administered to mice at days 28 and 56. The negative control group 
was administered 50 µL of PBS and the positive control group received one dose of 50 µg of 
immunogen in a total volume of 50 µL 1:1 CFA:PBS, followed by boosts in 50 µL PBS alone. 
Blood (10 µL ea.) was collected from tail snips of each mouse. The blood was left in 90 µL 
PBS at r.t. for ~30 min and centrifuged at 3000 rpm for 10 min to pellet red blood cells. 
Serum was stored at -20 °C. 
 
4.4.1. Detection of systemic IgG by ELISA 
Flat-bottom microtiter plates (Immulon™ 2HB, Thermo Scientific, USA) were coated with 
100 µL/well of a solution of streptavidin (Sigma-Aldrich) (5 µg.ml-1) in dH2O at 37 °C on a 
shaker/incubator overnight to dryness. A 4% BSA solution (150 µL) in 0.05% Tween-
20/PBS was added and incubated for 1 h at 37 °C. Plates were washed with PBS/Tween-20 
(0.05%) and 100 µL of peptide (5 µg.ml-1 [Biotin-Lys11]GnRH) in 0.05% Tween-20/0.1% 
NaN3/PBS was added for 1 h at 37 °C. Plates were washed and murine sera at a 1/100 
dilution (continued with a 1:2 dilution down the plate) in 1% BSA/PBS (100 µL/well) was 
added and incubated for 1.5 h at 37 °C in a humidified atmosphere. The sera were removed, 
the plates washed and 100 µL of a 1/3000 dilution of HRP-conjugated goat anti-mouse IgG 
(Jackson Laboratories/BioRad, USA) in 1% BSA/PBS was added. After 1 h at 37 °C, the 
plates were washed and 100 µL of o-phenylenediamine dihydrochloride substrate 
(SigmaFast, Sigma-Aldrich) was added. Plates were incubated in the dark for 30 min and the 
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absorbance of the solutions was then determined at a wavelength of 450 nm using a 
Molecular Devices SpectraMax 250 microplate reader. Cut-off was determined as the mean 
of PBS antisera plus 3 standard deviations. 
 
4.4.2. Statistics 
Statistical analysis was performed using a one-way ANOVA followed by the Tukey post hoc 
test. GraphPad Prism 5 software was used for statistical analysis, with p < 0.05 taken as 
statistically significant. 
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